Sleep
DSIP
Emideltide, delta sleep-inducing peptide
DSIP is a nine-amino-acid peptide first isolated in the 1970s from animals in deep sleep. It is not FDA-approved, and older human sleep studies produced weak or inconsistent results.
Key facts
- Commonly discussed for: sleep quality and insomnia.
- Evidence (C): Human evidence consists of small trials from the 1980s and early 1990s; a double-blind study of 16 chronic insomniacs found weak effects and concluded DSIP was unlikely to be of major therapeutic value.
- FDA status: Not recommended. On July 24, 2026 the PCAC voted 6-7 (1 abstention) against adding emideltide (DSIP) to the 503A Bulks List for opioid withdrawal, insomnia and narcolepsy, the only peptide rejected at that meeting.
- Legitimate access: No clear legal route yet.
- Last reviewed: October 1, 2026.
Read the deep dives
Sources
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology, 1992
- A clinical trial with DSIP. Eur Neurol, 1984
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)